MM-398 + Cyclophosphamide for Solid Tumors

This trial tests a combination of two drugs, MM-398 (Irinotecan Sucrosofate Liposome Injection) and Cyclophosphamide, to treat certain solid tumors. The main goal is to determine the highest safe dose of MM-398 when combined with Cyclophosphamide. The trial seeks participants with specific cancers, such as Ewing sarcoma or rhabdomyosarcoma, whose disease has progressed after previous treatments. Participants must have a confirmed diagnosis of these cancers and manageable daily symptoms. This study is crucial for understanding how these drugs work together to treat these challenging conditions. As a Phase 1 trial, the research focuses on how the treatment works in people, offering participants a chance to be among the first to receive this new combination therapy.

Previous studies have shown that MM-398 can cause common side effects, such as diarrhea, tiredness, vomiting, nausea, loss of appetite, and mouth sores. While the drug can be effective, it may cause discomfort during treatment.

The FDA has already approved Cyclophosphamide for other uses. Common side effects include a drop in blood cell counts, nausea, vomiting, hair loss, bladder irritation, and tiredness. Doctors have extensive experience managing these effects.

Unlike standard treatments for solid tumors, such as surgical removal, radiation therapy, and standard chemotherapy, MM-398 combined with cyclophosphamide offers a novel approach by utilizing a specialized delivery system. MM-398, which is a liposome-encapsulated form of irinotecan, enhances drug delivery directly to the tumor, potentially improving effectiveness and reducing side effects. Researchers are excited because this delivery mechanism could mean a higher concentration of the drug reaches the tumor site, while minimizing impact on healthy tissues. This innovative approach could lead to more effective treatment outcomes and a better quality of life for patients.

Research has shown that MM-398, a special form of the drug irinotecan, holds promise for treating various types of cancer. Studies have found that combining MM-398 with other drugs like 5-FU (a chemotherapy drug) can help patients with pancreatic cancer live longer and experience fewer side effects. Cyclophosphamide, another chemotherapy drug, stops cancer cells from growing. This trial will specifically evaluate the combination of MM-398 with cyclophosphamide. Although specific data on using MM-398 with cyclophosphamide is not yet available, the success of MM-398 with other treatments suggests this combination might be effective. MM-398 is known for delivering drugs effectively to tumors, potentially enhancing its cancer-fighting ability when used with cyclophosphamide.⁶⁷⁸⁹¹⁰